Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03380689
Other study ID # FNF008
Secondary ID
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date January 5, 2018
Est. completion date January 5, 2019

Study information

Verified date December 2017
Source Fujian Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase I Study of biweekly combination therapy with S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.


Description:

In several clinical studies from Japan and South Korea, the combination regimen of S-1 and irinotecan has shown efficacy in the treatment of advanced colorectal cancer, and a Phase III study(TRICOLORE) showed that the combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) is not inferior to the oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy. Here, we design this phase I study to explore the Chinese population's tolerability and efficacy of Biweekly SIRB Regimen(S-1/irinotecan/bevacizumab) and to explore the recommended dose of irinotecan in this regimen.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 5, 2019
Est. primary completion date July 5, 2018
Accepts healthy volunteers No
Gender All
Age group 20 Years to 75 Years
Eligibility Inclusion Criteria: - Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or metastatic disease, not amenable to curative therapy - Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) - Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more than 180 days after the end of such treatment. - Age =20 years - Life expectancy of at least 3 months - ECOG PS of 0 or 1 - Adequate function of major organs as defined below: - Hemoglobin =9.0g/dL - White blood cell count =3,500/mm3 - Neutrophil count =1,500/mm3 - Platelet count =100,000/mm3 - AST and ALT =100 U/L (<200 U/L in patients with liver metastasis) - Serum creatinine =1.2 mg/dL - Creatinine clearance estimate by the Cockcroft-Gault method >50 mL/min (reduce initial dosage by one step if =50 but <80 mL/min) - Able to take capsules orally. - No electrocardiographic abnormalities within 28 days before enrollment that would clinically preclude the execution of the study, as judged by the investigator. - Voluntary written informed consent. Exclusion Criteria: - Serious drug hypersensitivity or a history of drug allergy - Active double cancer - Active infections (e.g., patients with pyrexia of 38? or higher) - History of gastrointestinal perforation, intestinal tract paralysis, or ileus within 1 year. - Uncontrolled hypertension - Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart failure, renal failure, hepatic failure, or poorly controlled diabetes) - Moderate or severe ascites or pleural effusion requiring treatment - Watery diarrhea - Treatment with flucytosine or atazanavir sulfate - Metastasis to the CNS - Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing mothers. Men who are currently attempting to conceive children. - Severe mental disorder - Continuous treatment with steroids - Urine dipstick for proteinuria should be <2+ - Patient with a past history of thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism - Major surgical procedure, open biopsy, or clinically significant traumatic injury within 4 weeks - Long-term daily treatment with aspirin (>325 mg/day) - History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding - Judged ineligible for participation in the study by the investigator for safety reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
S-1
- S-1 is administered orally on days 1 to 7 of a 14-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Irinotecan
- CPT-11 was administrated as a 90-min intravenous infusion on day 1 of a 14-day cycle. Five escalating dose levels of CPT-11 were prepared, at an initial dose of 75mg/m2/day (level 1), stepping up to 100 (level 2), 125 (level 3), 150 (level 4) or 175 (level 5) mg/m2/day.
Bevacizumab
- Bevacizumab (5 mg/kg) is administered by intravenous infusion over the course of 30 to 90 min on day 1 of each 2-week cycle.

Locations

Country Name City State
China Rongbo Lin Fuzhou Fujian

Sponsors (1)

Lead Sponsor Collaborator
Fujian Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerance dose Maximum tolerance dose (MTD) is the dose of treatment in the cohort where there are 2 cases of DTL reported. From enrollment to completion of study. Estimated about 12 months.
Secondary Dose limiting toxicity Dose limiting toxicity (DLT) is referred to grade 3 non-hematological toxicity or grade 4 hematological toxicity according to NCI CTCAE 4.03 criteria. From enrollment to completion of study. Estimated about 12 months.
Secondary Objective response rate Clinical response of treatment according to RESIST v1.1 criteria (ORR, objective response rate). From enrollment to 6 months after treatment.
Secondary Progression-free survival The length of time from enrollment until the time of progression of disease (PFS, progression-free survival). From enrollment to progression of disease. Estimated about 6 months.
Secondary Overall survival The length of time from enrollment until the time of death (OS, overall survival). From enrollment to death of patients. Estimated about 1 year.
See also
  Status Clinical Trial Phase
Completed NCT01228734 - A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Phase 3
Completed NCT05178745 - A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
Completed NCT01591421 - P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. Phase 1/Phase 2
Withdrawn NCT05412706 - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy Phase 2
Withdrawn NCT04430985 - FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer Phase 2
Withdrawn NCT03182894 - Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05725200 - Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Phase 2
Terminated NCT03176264 - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer Phase 1
Completed NCT04866290 - HepaSphere™ Microspheres Prospective Registry
Not yet recruiting NCT06425133 - Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers Phase 2
Not yet recruiting NCT05531045 - 18FFDG PET/CT for Early Evaluation of Chemotherapy Efficacy in Metastatic Colic Adenocarcinoma
Withdrawn NCT03982173 - Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors Phase 2
Completed NCT02906059 - Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer Phase 1
Active, not recruiting NCT02575378 - Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer Phase 4
Withdrawn NCT02535988 - Abscopal Effect for Metastatic Colorectal Cancer Phase 2
Recruiting NCT02848807 - Chemotherapy-related Toxicity, Nutritional Status and Quality of Life N/A
Active, not recruiting NCT02077868 - Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Phase 3
Completed NCT02414009 - Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients Phase 2
Active, not recruiting NCT01949194 - Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers Phase 2
Withdrawn NCT01915472 - A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer Phase 2